Tyler Martin
CEO
Dr. Tyler Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine
adjuvant company, with headquarters in Lincoln, NE, based on intellectual
property from Memorial Sloan Kettering Cancer Center in New York, NY. Prior
to Adjuvance, he held senior leadership positions in a number of biotech
companies including Chiron, Sangamo, and Dynavax. He has led teams that filed
more than 100 Investigational New Drug (IND) Applications including two
adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-
B. In addition to other targets, Adjuvance is currently evaluating the utility of their
lead adjuvant with COVID-19 vaccines.